Comparison

SemaglutideRetatrutide

Semaglutide is the established GLP-1 mono agonist; Retatrutide is the third generation — a triple GLP-1 + GIP + glucagon agonist from Eli Lilly. Phase 2 shows the strongest numbers in the category.

Spec	A Semaglutide	B Retatrutide
Mechanism	GLP-1 mono agonist	GLP-1 + GIP + glucagon triple agonist
Weight loss (clinical)	14.9% / 68 weeks	24.2% / 48 weeks (Phase 2 NEJM 2023)
FDA status	Approved (2021)	Phase 3 (TRIUMPH trials)
Half-life	~7 days	~6 days
Glucagon component	No	Yes — raised thermogenesis
Available data	5+ years of publications	From 2023, still incomplete

Choose A when

Semaglutide

When you want an established protocol with long-term data and a predictable side-effect profile.

See full profile

Choose B when

Retatrutide

When you want maximum absolute weight loss and accept a less mature publication base.

See full profile

Verdict

Retatrutide leads on potency, but Semaglutide has 5+ years of open data. Retatrutide is not yet fully approved — TRIUMPH series continues through 2026.

Other comparisons

Keep exploring

Semaglutide vs Tirzepatide

Tirzepatide vs Retatrutide

BPC-157 vs TB-500

Ipamorelin vs CJC-1295

Last reviewed: 6 May 2026by PeptidLabs Editorial

Comparison

SemaglutideRetatrutide

Semaglutide is the established GLP-1 mono agonist; Retatrutide is the third generation — a triple GLP-1 + GIP + glucagon agonist from Eli Lilly. Phase 2 shows the strongest numbers in the category.

Spec	A Semaglutide	B Retatrutide
Mechanism	GLP-1 mono agonist	GLP-1 + GIP + glucagon triple agonist
Weight loss (clinical)	14.9% / 68 weeks	24.2% / 48 weeks (Phase 2 NEJM 2023)
FDA status	Approved (2021)	Phase 3 (TRIUMPH trials)
Half-life	~7 days	~6 days
Glucagon component	No	Yes — raised thermogenesis
Available data	5+ years of publications	From 2023, still incomplete

Choose A when

Semaglutide

When you want an established protocol with long-term data and a predictable side-effect profile.

See full profile

Choose B when

Retatrutide

When you want maximum absolute weight loss and accept a less mature publication base.

See full profile

Verdict

Retatrutide leads on potency, but Semaglutide has 5+ years of open data. Retatrutide is not yet fully approved — TRIUMPH series continues through 2026.

Other comparisons

Keep exploring

Semaglutide vs Tirzepatide

Tirzepatide vs Retatrutide

BPC-157 vs TB-500

Ipamorelin vs CJC-1295

Last reviewed: 6 May 2026by PeptidLabs Editorial